Zinc finger nucleases (ZFNs) have great potential for translational research and clinical use. Scientists succeeded in the efficient construction of functional ZFNs and the improvement of their genome ...

Delivering genome editing machinery into plant cells remains a challenge despite the dire need for high yield crops with enhanced nutritional value that are resistant to disease and resilient in the ...

Some genetic disorders—such as cystic fibrosis, hemophilia and Tay Sachs disease—involve many mutations in a person's genome, ...

MIT scientists have found a way to make gene editing far safer and more accurate — a breakthrough that could reshape how we ...

Advances in genome editing are transforming the treatment for rare genetic diseases, as seen in the case of seven-month-old ...

DURHAM, N.C., October 09, 2025--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS ® platform to develop in vivo ...

- Additional Data at ASGCT Annual Meeting Demonstrate Precision of HR-Based Approach with Genome-Wide Integration Assays Confirming On-Target Editing and No Off-Target Events - - New Data from GTx-mAb ...

Shondra Pruett-Miller has taken many paths in her career with her love of genome editing always as a guiding light. I still credit the success of my lab, now 20 years later, in large part to the ...

LONDON, GREATER LONDON, UNITED KINGDOM, October 14, 2025 /EINPresswire.com/ -- What Is The Expected Cagr For The Rare Disease Genome Editing Market Through 2025? The market size of genome editing for ...

DURHAM, N.C.--(BUSINESS WIRE)-- Precision BioSciences, Inc. (DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies, ...